₹-3.21
(Market cap
₹445 Cr
Recently Viewed
Clear AllMarket cap
₹445 Cr
Revenue (TTM)
₹207 Cr
P/E Ratio
17.1
P/B Ratio
1.5
Div. Yield
0 %
Value Research Rating
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹26 Cr
ROE
13.2 %
ROCE
17.3 %
Industry P/E
27.54
EV/EBITDA
12
Debt to Equity
0.2
Book Value
₹82.2
EPS
₹15.6
Face value
10
Shares outstanding
34,961,564
CFO
₹94.56 Cr
EBITDA
₹96.02 Cr
Net Profit
₹46.52 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kilitch Drugs
| -26.9 | -20.0 | -23.6 | -21.2 | 18.6 | 17.4 | 21.8 |
|
BSE Healthcare
| -1.9 | -1.8 | -2.4 | 7.7 | 24.3 | 13.4 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kilitch Drugs
| 9.5 | -11.4 | 137.3 | -37.6 | 146.7 | -24.0 | -21.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kilitch Drugs
|
128.1 | 445.4 | 207.1 | 24.8 | 12.3 | 11.1 | 17.1 | 1.5 |
| 2,806.0 | 34,960.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.5 | 7.6 | |
| 8,299.0 | 20,728.8 | 2,177.5 | 200.9 | 11.3 | 26.5 | 103.2 | 24.9 | |
| 1,708.4 | 12,960.8 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.1 | 3.9 | |
| 1,371.4 | 19,077.4 | 3,078.2 | 469.4 | 26.4 | 14.9 | 44.2 | 5.3 | |
| 2,005.4 | 32,172.0 | 4,193.0 | 753.8 | 22.7 | 20.8 | 42.7 | 8.0 | |
| 4,868.6 | 22,272.7 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.1 | 5.6 | |
| 4,943.0 | 8,241.6 | 1,348.5 | 293.5 | 28.1 | 50.7 | 28.1 | 11.8 | |
| 420.1 | 8,253.6 | 1,432.0 | 149.0 | 19.1 | 7.9 | 55 | 3.3 | |
| 1,000.0 | 9,235.7 | 4,725.6 | 528.7 | 14.9 | 20.7 | 18.1 | 3.1 |
No Review & Analysis are available.
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India, Asia, Africa, Latin America, and Commonwealth of Independent States. The company offers various parenteral, nasal, and topical products, such... as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungals, corticosteroids, and other drugs, as well as vaccines and veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral solid dosage formulations, including tablets, capsules, dry syrup, and oral powder for antibiotics, anti-diabetics, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products comprising Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care; herbal products used for sore throat, prostate problems, and as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical device comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces stomach acid; SRO kit for treating childhood diarrhea; 9-Vit used in surgery, extensive burns, fractures, and other trauma; and HPure for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India. Read more
Incorporated
1992
Chairman
--
Managing Director
Mukund P Mehta
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Kilitch Drugs (India) Ltd is ₹128.06 (NSE) and ₹128.35 (BSE) as of 10-Apr-2026 IST. Kilitch Drugs (India) Ltd has given a return of 18.63% in the last 3 years.
The P/E ratio of Kilitch Drugs (India) Ltd is 17.10 times as on 10-Apr-2026, a 38 discount to its peers’ median range of 27.54 times.
The P/B ratio of Kilitch Drugs (India) Ltd is 1.55 times as on 10-Apr-2026, a 66 discount to its peers’ median range of 4.59 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
21.31
|
2.88
|
|
2024
|
42.02
|
3.56
|
|
2023
|
20.81
|
1.49
|
|
2022
|
35.47
|
1.92
|
|
2021
|
34.21
|
0.99
|
The 52-week high and low of Kilitch Drugs (India) Ltd are Rs 250.00 and Rs 117.25 as of 10-Apr-2026.
Kilitch Drugs (India) Ltd has a market capitalisation of ₹ 445 Cr as on 10-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kilitch Drugs (India) Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.